A milestone for NeuroEthics
Neurotechnologies are no longer confined to research laboratories. They are fully integrated in our societies, whether in the medical field or beyond. The capacity of these technologies to probe and interfere with the brain activity of an individual questions the notions of identity, integrity and autonomy of human beings. Recent initiatives aim to help governments […]
The benefits of collecting EEG neuroimaging insights in clinical trials.
In clinical trials, brain monitoring EEG is facilitating the measurement of complex clinical endpoints. EEG as a biomarker provides safe, objective and repeatable data enabling a deeper understanding of the pharmacological effects of the drug early in its development.
A milestone for NeuroEthics.
The capacity of neurotechnologies to probe and interfere with brain activity challenges notions of identity, integrity and autonomy of human being. Recent initiatives aim to help actors in the field anticipate and address ethical, legal and social challenges, while promoting innovation in this area.
NeuroDesign: to perfect the symbiosis between a product and the user experience.
One of the key aspects of product strategy is to generate, identify and leverage insights that will provide the foundation to reach business objectives. Today, data generated through real time brain monitoring can accompany teams throughout the design process.
[SAVE THE DATE] – AI, conquering emotions in Health!
On Tuesday, November 16, 2021, at 11am, come and listen to Giuseppe Spinelli at the microphone of Pascal Becache on the occasion of the 4th Webinar #PharmaTalk of Digital Pharma Lab. Accompanied by Antoine Groheux, they will discuss about "AI, conquering emotions in Health!".
The path to ISO 13485.
Implementing a quality approach within a start-up poses particular difficulties linked to the context of innovation, agility and rapid growth. However, such an approach is essential to guarantee the sustainability of its activities and to enable it to become a leader in its market.
